PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2020 | 10 | 1 | 15-17
Article title

Long-term disease control during TAS-102 therapy in the VI line treatment in a 73-year-old mCRC patient. A case report

Content
Title variants
Languages of publication
EN
Abstracts
EN
A case of 73-year-old patient with metastatic colorectal cancer who underwent trifluridine/tipiracil therapy within the VI line was presented. Treatment with trifluridine/tipiracil allowed to achieve stabilization of the existing cancer for nearly 7 months.
Discipline
Publisher

Journal
Year
Volume
10
Issue
1
Pages
15-17
Physical description
Contributors
author
  • 1. Department of Oncology, Medical University of Bialystok, Poland. 2. Department of Oncology with Daytime Chemotherapy Unit, Bialystok Oncology Centre, Poland
author
  • 1. Department of Oncology, Medical University of Bialystok, Poland. 2. Department of Oncology with Daytime Chemotherapy Unit, Bialystok Oncology Centre, Poland
author
  • Department of Radiology, Bialostockie Oncology Center
  • 1. Department of Oncology, Medical University of Bialystok, Poland. 2. Department of Oncology with Daytime Chemotherapy Unit, Bialystok Oncology Centre, Poland
References
  • 1. Mayer RJ, Van Cutsem E, Falcone A et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372(20): 1909-19.
  • 2. Xu J, Kim TW, Shen L et al. Results of a randomized, double-blind, placebo-controlled, Phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients With previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2018; 36(4): 350-8.
  • 3. Kwakman JJM, Vink G, Vestjens JH et al. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. Int J Clin Oncol. 2018; 23: 482-9.
  • 4. Cremolini C, Rossini D, Martinelli E et al. Trifluridine/tipiracil (TAS-102) in refractory metastatic colorectal cancer: a multicenter register in the frame of the Italian compassionate use program. Oncologist. 2018; 23: 1178-87.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-13039fc4-2419-418d-91ae-430099ad4549
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.